Clinical Trials

Enrolling Studies – To inquire about any of the studies, please email: Derm.Research@BrownPhysicians.org

TRuE-AD3

PI:
Jennie Muglia, MD

Sponsor:
Incyte

Study Phase:
Phase 3

Indicated For:
Children from the ages of 2 years old to 11 years old with AD for at least 3 months, and IGA for to 3 and BSA of 3% to 20% (excluding the scalp)

Study Drug:
Topical cream (Ruxolitinib)

Inclusion Criteria:
This study is looking for patients ages 2 to 11 years of age with atopic dermatitis also known as eczema. Patient have to been diagnosed with eczema for at least 3 months prior to entering the study.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

Otezla Study

PI:
Abrar Qureshi, MD

Sponsor:
Amgen

Study Phase:
Phase 4

Indicated For:
Adults with Early, oligoarticular
psoriatic arthritis despite initial stable treatment with either non-steroidal anti-inflammatory
drugs (NSAIDs) and/or more than 1 conventional synthetic disease-modifying antirheumatic
drugs (DMARD)
(Subjects will be randomly assigned in a 2:1 ratio to either apremilast 30 mg BID
or placebo, but all patients get study drug by Week 24)

Study Drug:
Tablets (BID)

Inclusion Criteria:
The study is looking for participants between the ages of 18 and older with a diagnosis of psoariatic arthritis no more than 24 months prior. Patients will need 1-4 swollen and tender joints to apply.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

ILUMYA

PI:
Carlos Wambier, PhD, MD

Sponsor:
Sun Pharma

Study Phase:
Investigator Initiated

Indicated For:
Moderate to Severe Psoriasis (age 35 or older)

Study Drug:
Injection – administered at Study Visits

Inclusion Criteria:
This study is for patients 35 years of age or older with moderate to severe psoriasis ands are willing to go on ILUMYA for the first time to manage the symptoms of psoriasis. Patients are also needed for this study that have psoriasis, and will not be going on ILUMYA for a one time blood draw at the beginning of the study.

Status:
Enrolling Soon/ accepting potential subjects for pre-screening

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.

The Galderma Study

PI:
Jennie Muglia, MD

Sponsor:
Galderma

Study Phase:
Phase 3

Indicated For:
Patients 18 and over will subjects with Prurigo Nodularis (PN) will be randomized 2:1 to receive either nemolizumab (CD14152) or placebo. A clinical dx of PN for at least 6 months on the upper limbs, trunk, and/ or lower limbs with at least 20 nodules on the entire body

Study Drug:
Injection- administered at Study Visits

Inclusion Criteria:
This study is for patient diagnosed with prurigo nodularis for at least 6 months prior to entering the study. The study participants will receive injections every 4 weeks.

Status:
Enrolling

Compensation:
All eligible patients will be compensated for their time and travel to attend study visits.